8-KEarnings & ResultsExhibits & Filings

Elevance Health, Inc. 8-K Report, Financial Results (Jul 19, 2023)

Filed July 19, 2023For Securities:ELV

Summary

Elevance Health, Inc. (ELV) filed an 8-K on July 19, 2023, to report its financial results for the second quarter ended June 30, 2023. The filing primarily consists of a press release detailing these results. While specific financial figures are not detailed within the 8-K document itself, investors are directed to Exhibit 99.1, the press release, for comprehensive details on revenue, earnings, and other key performance indicators. This report serves as notification of the earnings release and includes standard forward-looking statements and risk disclosures common in such filings. Investors should refer to the furnished press release for the actual financial performance and outlook, as the 8-K itself is procedural. The accompanying risk factors highlight potential challenges such as healthcare cost trends, regulatory changes, cyber security threats, and competitive pressures that could impact future results.

Key Highlights

  • 1Elevance Health announced its Q2 2023 financial results via an 8-K filing on July 19, 2023.
  • 2The primary content of the 8-K is a furnished press release (Exhibit 99.1) containing the detailed financial results for the quarter ended June 30, 2023.
  • 3Investors are advised to consult the press release for specific financial performance data, including revenue and earnings.
  • 4The filing includes a standard cautionary note regarding forward-looking statements, emphasizing that actual results may differ due to various risks and uncertainties.
  • 5Key risk factors mentioned include healthcare cost trends, regulatory impacts, cybersecurity risks, and competitive pressures.
  • 6The report does not contain new material agreements or significant corporate events beyond the earnings announcement.

Frequently Asked Questions

The specific financial results for the quarter ended June 30, 2023, are detailed in the press release furnished as Exhibit 99.1 to the 8-K filing. Investors should review this exhibit for detailed figures on revenue, earnings, and other financial metrics.

Elevance Health highlights several risks, including trends in healthcare costs and utilization rates, potential impacts from new or changed healthcare laws and regulations, cybersecurity threats and data security breaches, competitive pressures, and risks associated with government programs like Medicare and Medicaid.

No, this 8-K filing is primarily for the purpose of reporting the company's financial results for the second quarter of 2023. It does not appear to announce any new material agreements, acquisitions, or other significant corporate events.

The filing explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into any Securities Act of 1933 filings, unless expressly set forth.